Skip to main content

Rockwell Medical Value Stock - Dividend - Research Selection

Rockwell medical

ISIN: US7743741024 , WKN: 916118

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Rockwell Medical, Inc. operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company\'s lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment. It also provides Calcitriol, a generic active vitamin D injection, which is indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its concentrated dialysate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient\'s bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. The company\'s target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


What's Going On With Rockwell Medical Stock Wednesday?

2026-05-20
Rockwell Medical (RMTI) spikes 6.4% premarket. Discover key support and resistance levels as the stock tests its 20-day moving average.

Rockwell Medical Renews And Extends Its Product Purchase Agreement With aQua Dialysis

2026-05-20
The Agreement, which includes supply and purchasing commitments, will be in effect for two years with options to renew for two additional one-year periods. Under the Agreement, Rockwell Medical will continue to supply

Rockwell Medical signs new 3-year product purchase agreement with Heritage Dialysis

2026-05-14
Rockwell Medical Inc: Rockwell Medical signs new 3-year product purchase agreement with Heritage Dialysis Rockwell Medical Inc announces three-year product purchase agreement with Heritage...

Rockwell Medical Signs Three-Year Product Purchase Agreement With Heritage Dialysis

2026-05-14
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today

Rockwell Medical, Inc. 2026 Q1 - Results - Earnings Call Presentation

2026-05-12
2026-05-12. The following slide deck was published by Rockwell Medical, Inc.

Rockwell Medical, Inc. (RMTI) Q1 2026 Earnings Call Transcript

2026-05-07
Rockwell Medical, Inc. (RMTI) Q1 2026 Earnings Call May 7, 2026 8:00 AM EDTCompany ParticipantsHeather Hunter - Senior VP & COOMark Strobeck -...

Transcript : Rockwell Medical, Inc., Q1 2026 Earnings Call, May 07, 2026

2026-05-07
Presentation Operator MessageOperator Hello, everyone. Thank you for joining us and welcome to Rockwell Medical's First Quarter 2026 Results Conference Call and Webcast. Please note, this event is...

Rockwell Medical (NASDAQ:RMTI) Posts Q1 Miss, But Profitability Roadmap Drives Pre-Market Optimism

2026-05-07
Rockwell Medical (RMTI) reported a slight Q1 2026 earnings miss, but the stock is rising on strong 2026 profitability guidance, including positive adjusted EBITDA and operating cash flow.

Rockwell Medical: Q1 Earnings Snapshot

2026-05-07
WIXOM, Mich. — WIXOM, Mich. — Rockwell Medical Inc. on Thursday reported a loss of $1.6 million in its first quarter. The Wixom, Michigan-based company said it had a loss of 4 cents per...

Rockwell Medical Raises FY2026 Sales Guidance from $65.000M-$70.000M to $70.000M-$75.000M vs $73.769M Est

2026-05-07
Rockwell Medical updates its 2026 annual guidance as follows: 2026 Annual GuidanceNet Sales$70.0M to $75.0MGross Margin18% to 22%Adjusted EBITDA$1.0M to $2.0MOperating Cash FlowPositive